Related Experiment Video
Updated: Jul 5, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
[Coat's disease treated with bevacizumab (Avastin)]
L G Alvarez-Rivera1, M L Abraham-Marín, H J Flores-Orta
1Asociación Para Evitar la Ceguera en México IAP Hospital Dr. Luis Sánchez Bulnes, Ciudad de México, México.
Case Report:
We report a case of Coats' disease in a 10-year-old-girl who presented with a profound visual deficit, exudative retinal detachment, vascular telangiectasias and subretinal lipid, who underwent treatment with an intravitreal injection of bevacizumab (AVASTIN(TM)). Serial examinations documented an involutional response with a reduction of the subretinal fluid, exudates and macular thickness.
Discussion:
The aetiology of Coats' disease remains uncertain, as does its optimal management. Although resolution of a case depends partially on age, and can even occur spontaneously on rare occasions, intravitreal injections of bevacizumab should be considered when planning treatment.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

